pocketful logo light
pocketful logo light
Shukra Pharmaceuticals Ltd logo

Shukra Pharmaceuticals Ltd

NSE: BSE: 524632

30.98

(2.79%)

Mon, 15 Jun 2026, 07:06 am

Shukra Pharmaceuticals Share Price Live Chart

1 Day

(2.79%)

No Result Found

Summary

  • Market Cap (in Cr)

    1269.41

  • Net Profit (in Cr)

    9.58

  • P/B

    15.17

  • Sector P/E

    33.76

  • P/E

    99.32

  • EV/EBITDA

    56.04

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.81

  • ROCE (Industry)

    16.40

  • RONW (Industry)

    14.39

  • ROE

    15.90

  • ROCE

    21.76

  • Debt/Equity

    0.06

  • EPS (TTM)

    0.50

  • Dividend Yield

    0

  • Book Value

    2.05

  • Interest Cover

    23.61

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters50.9650.9650.9650.9650.96
FII00000
DII0.110.110.110.110.11
Public48.9348.9348.9348.9348.93
Government00000

Read More

Technical Analysis

RSI

49.73

MACD

-0.36

50 DMA

31.47

200 DMA

38.08

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic48.2039.2034.0930.2025.0921.2012.20
Fibonacci39.2035.7633.6330.2026.7624.6321.20
Camarilla31.4630.6429.8130.2028.1627.3426.52

Pivots Level: Classic

R3

+18.00

48.20

R2

+9.00

39.20

R1

+3.90

34.09

30.20
30.20
Pivot Point
LTP: 30.51

S1

-5.10

25.09

S2

-9.00

21.20

S3

-18.00

12.20

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    30.19

  • 20-EMA

    30.28

  • 30-EMA

    30.73

  • 50-EMA

    32.05

  • 100-EMA

    34.53

  • 200-EMA

    34.02

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
07 May 2026board-meetingsAccounts, Final Dividend
04 Feb 2026board-meetingsQuarterly Results
13 Nov 2025board-meetingsQuarterly Results
04 Oct 2025egm
30 Aug 2025agm
18 Aug 2025dividendFinal Dividend - Rs. - 0.0118 Sept 2025
04 Jun 2025dividend₹0.01 Dividend /Share18 Sept 2025
21 Feb 2025splitStock Split From Rs.10 to Rs.121 Mar 2025
29 Jan 2025split1:10 Splits of Equity Shares21 Mar 2025
15 Sept 2024agm

Read More

Peer Comparison

Shukra Pharmaceuticals Ltd logo

Shukra Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Shukra Pharmaceuticals Ltd About

Shukra Pharmaceuticals is engaged primarily in the business of manufacture and marketing of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1993

Headquarters

CEO

Dakshesh Shah

Employees

Contact

Website icon

Website

http://www.shukrapharmaceuticals.com

Email icon

Email

info@shukrapharmaceuticals.com

Phone icon

Phone

91-079-66522247/27498515

Location icon

Location

3 rd Floor Dev House, Opp WIAA Office Judges Bungalo, Ahmedabad, Gujarat, 380054

Read More

Shukra Pharmaceuticals Ltd Company History

YearHistory
No Result Found

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
No Result Found

Read More

Shukra Pharmaceuticals Ltd News

Shukra Pharmaceuticals to ratify EGM resolution

Shukra Pharmaceuticals Ltd. will hold a board meeting on June 10, 2026, to ratify a member's resolution passed in the EGM dated November 1, 2025.

05 Jun 2026

companies

Shukra Pharma FY26 Results Published in Newspapers Under Reg 47

Shukra Pharmaceuticals published its FY26 audited standalone results in Business Standard and Jai Hind newspapers per SEBI Regulation 47. FY26 net profit more than doubled to ₹2,204.79 lakhs.

09 May 2026

companies

Shukra Pharma Q4 EBITDA Margin at 10.91% vs 55.16% YoY

Shukra Pharmaceuticals Q4 EBITDA stood at 6.9M rupees vs 73M YoY; EBITDA margin at 10.91% vs 55.16%. FY26 net profit more than doubled to ₹2,204.79 lakhs.

08 May 2026

companies

Shukra Pharma Posts FY26 Net Profit of ₹2,204.79 Lakhs

Shukra Pharmaceuticals reports standalone net profit of ₹2,204.79 lakhs for FY26, up from ₹957.51 lakhs in FY25, with revenue from operations rising to ₹5,670.61 lakhs.

07 May 2026

companies

Shukra Pharmaceuticals Board Meet on May 7, 2026

Shukra Pharmaceuticals schedules board meeting for May 7, 2026 to approve Q4 FY26 audited results and recommend final dividend for FY 2025-26.

29 Apr 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number